Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O, an antibiotic...
Gujarat Themis Biosyn reported revenue of 1.51 billion INR for fiscal year 2025, down 11.2% from fiscal year 2024, and net income of 487.72 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 433.68 million INR, up 9.7% from a year before. Its market capitalization was 47.28 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.